RVT-501 is a highly potent and selective topical phosphodiesterase-4 inhibitor. Dermavant is running a phase 2 clinical program for RVT-501 in patients with mild-to-moderate atopic dermatitis.
RVT-502 is a topical formulation of the dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor cerdulatinib. Dermavant is developing RVT-502 for a variety of serious dermatologic conditions.
RVT-503 is a preclinical investigational drug candidate being developed for the treatment of acne.
RVT-504 is a combination of a muscarinic antagonist with a muscarinic agonist being developed as an oral therapy for the treatment of hyperhidrosis.
RVT-201 is a caspase-1 inhibitor that acts to inhibit the production of inflammatory cytokines such as IL-ß and IL-18. Dermavant is developing RVT-201 for multiple inflammatory skin conditions.